Glucagon-like peptide 1 and the cardiovascular system

Current Diabetes Reviews

Volumn 10, Issue 5, 2014, Pages 302-310

  Fava, Stephen ^a  

^a UNIVERSITY OF MALTA   (Malta)

Author keywords

Cardiovascular; Glucagon like peptide 1; Incretin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIRAGLUTIDE; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; TRIACYLGLYCEROL;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; HEART FAILURE; HEART PROTECTION; HEART RATE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INSULIN RELEASE; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; PRIORITY JOURNAL; REPERFUSION INJURY; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DIABETES MELLITUS; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INFLAMMATION; METABOLISM; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; BLOOD GLUCOSE; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INFLAMMATION; INSULIN-SECRETING CELLS; OXIDATIVE STRESS; TRIGLYCERIDES;

EID: 84925882595     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399810666141030125830     Document Type: Article

References (135)

1. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63(2): 492-8.
2. Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulinreleasing polypeptide. Endocr Rev 1995; 16(3): 390-410.
3. Drucker DJ. Biologic actions and therapeutic potential of the glucagon- like peptides. Nature Clinical Practice. Endocrinology and Metabolism 2005; 1: 22-31.
4. Teff KL, Elliott SS, Tschöp M, Kieffer TJ, Rader D, Heiman M, Townsend RR, Keim NL, D'Alessio D, Havel PJ. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab 2004; 89(6): 2963-72.
5. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagonlike peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44(9): 1126-31.
6. Zhu L, Tamvakopoulos C, Xie D, et al.The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1- 38) J Biol Chem 2003; 278: 22418-23.
7. Druce MR, Bloom SR. Oxyntomodulin: a novel potential treatment for obesity. Treatments in Endocrinology 2006; 5: 265-72.
8. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon- like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36(8): 741-4.
9. Seino Y, Rasmussen MF, Clauson P, Kaku K. The once-daily human glucagon-like peptide-1 analog, liraglutide, improves b-cell function in Japanese patients with type 2 diabetes. J Diabetes Inv 2012; 3(4): 388-95.
10. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91(11): 4612-9.
11. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007; 92(4): 1249-55.
12. Dhanesha N, Joharapurkar A, Shah G, Dhote V, Kshirsagar S, Bahekar R, Jain M. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase. J Diabetes 2012; 4(4): 369-77.
13. Park JH, Kim SJ, Park SH, Son DG, Bae JH, Kim HK, Han J, Song DK. Glucagon-like peptide-1 enhances glucokinase activity in pancreatic b-cells through the association of Epac2 with Rim2 and Rab3A. Glucagon-like peptide-1 enhances glucokinase activity in pancreatic b-cells through the association of Epac2 with Rim2 and Rab3A. Endocrinology 2012; 153(2): 574-82.
14. Ding SY, Nkobena A, Kraft CA, Markwardt ML, Rizzo MA. Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic beta cells. J Biol Chem 2011; 286(19): 16768-74.
15. Arnette D, Gibson TB, Lawrence MC, et al.Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic beta cells. J Biol Chem 2003; 278: 32517-25.
16. Selway J, Rigatti R, Storey N, Lu J, Willars GB, Herbert TP. Evidence that Ca2+ within the microdomain of the L-type voltage gated Ca2+ channel activates ERK in MIN6 cells in response to glucagon-like peptide-1. PLoS One 2012; 7(3): e3300.
17. Khoo S, Gibson TB, Arnette D, Lawrence M, January B, McGlynn K, Vanderbilt CA, Griffen SC, German MS, Cobb MH. MAP kinases and their roles in pancreatic beta-cells. Cell Biochem Biophys 2004; 40(3 Suppl): 191-200.
18. Kim MK, Cho JH, Lee JJ, Cheong YH, Son MH, Lee KJ. Differential protective effects of exenatide, an agonist of GLP-1 receptor and Piragliatin, a glucokinase activator in beta cell response to streptozotocin-induced and endoplasmic reticulum stresses. PLoS One 2013; 8(9): e73340.
19. Dhanesha N, Joharapurkar A, Shah G, Dhote V, Kshirsagar S, Bahekar R, Jain M. Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect. Pharmacol Rep 2012; 64(1): 140-9.
20. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010; 212(1): 217-22.
21. Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2049-57.
22. Patel VJ, Joharapurkar AA, Shah GB, Jain MR. Effect of GLP-1 Based Therapies on Diabetic Dyslipidemia. Curr Diabetes Rev 2014 Jul 6. [Epub ahead of print].
23. Qin X, Shen H, Liu M, Yang Q, Zheng S, Sabo M, D'Alessio DA, Tso P. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol. 2005; 288(5): G943-9.
24. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273(5 Pt 1): E981-8.
25. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276(5 Pt 2): R1541-4.
26. Fava S. Expert Rev Cardiovasc Ther. Role of postprandial hyperglycemia in cardiovascular disease. 2008; 6(6): 859-72.
27. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101(3): 515-20.
28. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143(11): 4397-408.
29. Li L, El-Kholy W, Rhodes CJ, Brubaker PL. Glucagon-like peptide- 1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 2005; 48(7): 1339-49.
30. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL. Glucagonlike peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004; 47(3): 478-87.
31. Wei Q, Sun YQ, Zhang J. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic b-cell line. Peptides 2012; 37(1): 18-24.
32. Kim JY, Lim DM, Park HS, Moon CI, Choi KJ, Lee SK. Exendin-4 protects against sulfonylurea-induced b-cell apoptosis. J Pharma Sci 2012; 118: 65-74.
33. Fan R, Li X, Gu X, Chan JC, Xu G. Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Diabetes Obes Metab 2010; 12(9): 815-24.
34. Duttaroy A, Voelker F, Merriam K, Zhang X, Ren X, Subramanian K, Hughes TE, Burkey BF. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol 2011; 650(2-3): 703-7.
35. Han SJ, Choi SE, Kang Y, Jung JG, Yi SA, Kim HJ, Lee KW, Kim DJ. Effect of sitagliptin plus metformin on b-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats. Diabetes Res Clin Pract 2011; 92(2): 213-22.
36. Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Järvinen H, Diamant M. Effects of exenatide on measures of b-cell function after 3 years in metformintreated patients with type 2 diabetes. Diabetes Care 2011; 34(9): 2041-7.
37. Park YJ, Ao Z, Kieffer TJ, Chen H, Safikhan N, Thompson DM, Meloche M, Warnock GL, Marzban L. The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation. Diabetologia 2013; 56(3): 508-19.
38. Suarez-Pinzon WL, Lakey JR, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant 2008; 17(6): 631-40.
39. Favaro E, Granata R, Miceli I, Baragli A, Settanni F, Cavallo Perin P, Ghigo E, Camussi G, Zanone MM. The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3- kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways. Diabetologia 2012; 55(4): 1058-70.
40. Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, Aguilar-Diosdado M. Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal- regulated kinase 1/2 pathway inhibition: protective role of glucagon- like peptide -1. J Mol Endocrinol 2008; 41(1): 35-44.
41. Bullock, BP. Heller RS. Habener, JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-78.
42. Amato A, Baldassano S, Liotta R, Serio R, Mulè F. Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle. J Endocrinol 2014; 221(1): 29-37.
43. Richter G, Feddersen O, Wagner U, Barth P, Göke R, and Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol Lung Cell Mol Physiol 1993; 265: L374-L381.
44. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, et al.Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51: 1584-92.
45. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004; 287(6): E1209-15.
46. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117(18): 2340-50.
47. Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, Matsumoto M, Mizutani K, Park K, Cahill C, Nishikawa S, Rask- Madsen C, King GL. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCb activation in diabetes. Diabetes 2012; 61(11): 2967-79.
48. Han L, Yu Y, Sun X, Wang B. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res Clin Pract 2012; 97(3): 453-60.
49. Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab Vasc Dis Res 2011; 8(2): 117-24.
50. Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, Kodama K, Sakamoto Y, Kotooka N, Hirase T, Node K. The glucagon- like peptide 1 analog liraglutide reduces TNF-b-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012; 221(2): 375-82.
51. Ding L, Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin 2012; 33(1): 75-81.
52. Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, Kasai K, Hayashi T. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts antiinflammatory action in endothelial cells. Diabetologia 2010; 53(10): 2256-63.
53. Ha SJ, Kim W, Woo JS, Kim JB, Kim SJ, Kim WS, Kim MK, Cheng XW, Kim KS. Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels. Arterioscler Thromb Vasc Biol 2012; 32(2): 474-80.
54. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 2010; 33(5): 1028-30.
55. Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F, Gnasso A. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res 2013; 10(1): 72-7.
56. Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1- dependent mechanism. Hypertension 2012; 60(3): 833-41.
57. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011; 34(9): 2072-7.
58. Lee W, Ku SK, Park EJ, Na DH, Kim KM, Bae JS. Exendin-4 Inhibits HMGB1-Induced Inflammatory Responses in HUVECs and in Murine Polymicrobial Sepsis. Inflammation 2014; 37(5): 1876-88.
59. Krasner NM, Ido Y, Ruderman NB, Cacicedo JM. Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS One 2014; 9(5): e97554.
60. Forst T, Michelson G, Ratter F, Weber MM, Anders S, Mitry M, Wilhelm B, Pfützner A. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med 2012; 29(9): 1115-8.
61. Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon- like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009; 201(1): 59-66.
62. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59(4): 1030-7.
63. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase- IV inhibition. Diabetes Care 2012; 35(10): 2076-82.
64. Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther 2013; 27(5): 371-80.
65. Schisano B, Harte AL, Lois K, Saravanan P, Al-Daghri N, Al-Attas O, Knudsen LB, McTernan PG, Ceriello A, Tripathi G. GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress. Regul Pept 2012; 174(1-3): 46-52.
66. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010; 30(7): 1407-14.
67. Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R, Su T, Ma X, Zeng C, Wang H, Ren J, Cao F. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes 2013; 62(5): 1697-708.
68. Erdogdu O, Eriksson L, Xu H, Sjöholm A, Zhang Q, Nyström T. Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. Mol Endocrinol 2013; 50(2): 229-41.
69. Younce CW, Burmeister MA, Ayala JE. Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol 2013; 304(6): C508-18.
70. Zhou SJ, Bai L, Lv L, Chen R, Li CJ, Liu XY, Yu DM, Yu P. Liraglutide ameliorates renal injury in streptozotocin-induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor-bB pathway. Mol Med Rep 2014; 10(5): 2587-94.
71. Zhu W, Zhong C, Yu Y, Li K. Acute effects of hyperglycaemia with and without exercise on endothelial function in healthy young men. Eur J Appl Physiol 2007; 99(6), 585-91.
72. Lee IK, Kim HS, Bae JH. Endothelial dysfunction: its relationship with acute hyperglycaemia and hyperlipidemia. Int J Clin Pract Suppl 2002; 129: 59-64.
73. Watanabe K, Oba K, Suzuki T, Ouchi M, Suzuki K, Futami-Suda S, Sekimizu K, Yamamoto N, Nakano H. Oral glucose loading attenuates endothelial function in normal individual. Eur J Clin Invest 2001; 41: 465-73.
74. Ceriello, A. Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of shortand long-term simvastatin treatment. Circulation 2002; 106; 1211-18.
75. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295(14): 1681-7.
76. Yano M, Hasegawa G, Ishii M, et al.Short-term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep 2004; 9(2): 111-6.
77. de Castro SH, Castro-Faria-Neto HC, Gomes MB. Association of postprandial hyperglycemia with in vitro LDL oxidation in nonsmoking patients with type 1 diabetes--a cross-sectional study. Rev Diabet Stud 2005; 2(3): 157-64.
78. Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005; 112: 179-84.
79. Cai L, Li W, Wang G, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in the mouse myocardium. Diabetes 2002; 51: 1938-48.
80. Anderson RA, Evans LM, Ellis GR, et al.Prolonged deterioration of endothelial dysfunction in response to postprandial lipaemia is attenuated by vitamin C in Type 2 diabetes. Diabet Med 2006; 23(3): 258-64.
81. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006; 91: 837-42.
82. Rudofsky G Jr, Reismann P, Schiekofer S, et al.Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NFkappaB activation in PBMCs. Horm Metab Res 2004; 36(9): 630-8.
83. Yang Q, Zhang Z, Gregg EW, Flanders WD, Merritt R, Hu FB. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med 2014; 174(4): 516-24.
84. The DECODE Study group. European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999; 354(9179): 617-21.
85. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26(3): 688-96.
86. Ning F, Tuomilehto J, Pyörälä K, Onat A, Söderberg S, Qiao Q; DECODE Study Group. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 2010; 33(10): 2211-6.
87. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-83.
88. de Vegt F, Dekker JM, Ruhé HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926-31.
89. Shaw JE Hodge AM, de Courten M, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999; 42: 1050-54.
90. Patel YR, Kirkman MS, Considine RV, Hannon TS, Mather KJ. Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes. Diabetes Metab Res Rev 2013; 29(7): 582-91.
91. Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2011; 10: 19.
92. Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, Miyazaki A, Hirano T. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 2011; 54(10): 2649-59.
93. Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. Diab Vasc Dis Res 2013; 10(4): 353-60.
94. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 58(2): 157-66.
95. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim- Mitsuyama S, Takeya M, Ogawa H. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012; 59(3): 265-76.
96. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124(21): 2338-49.
97. Terasaki M, Nagashima M, Nohtomi K, Kohashi K, Tomoyasu M, Sinmura K, Nogi Y, Katayama Y, Sato K, Itoh F, Watanabe T, Hirano T. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice PLoS One 2013; 8(8): e70933.
98. Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, Elahi D, Shannon RP. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005; 312(1): 303-8.
99. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009; 53(6): 501-10.
100. Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR, Harpel MR, Willette RN, Lepore JJ, Jucker BM. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One 2011; 6(8)
101. Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon- like peptide 1 can directly protect the heart against ischemia/ reperfusion injury. Diabetes 2005; 54(1): 146-51.
102. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon- like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacinginduced dilated cardiomyopathy. Circulation 2004; 110(8): 955-61.
103. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 2008; 1(3): 153-60.
104. Takahashi A, Asakura M, Ito S, Min KD, Shindo K, Yan Y, Liao Y, Yamazaki S, Sanada S, Asano Y, Ishibashi-Ueda H, Takashima S, Minamino T, Asanuma H, Mochizuki N, Kitakaze M. Dipeptidylpeptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. Am J Physiol Heart Circ Physiol 2013; 304(10): H1361-9.
105. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 24; 3(1).
106. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013; 15(8): 737-49.
107. Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, Rajagopalan S. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014; 27(1): 130-9.
108. Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolisso G. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013; 227(2): 349-54.
109. Rizzo M, Chandalia M, Patti AM, Di Bartolo V, Rizvi AA, Montalto G, Abate N. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol 2014; 13(1): 49.
110. Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 2012; 98(5): 408-1.
111. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109(8): 962-5.
112. Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NE, Dutka DP. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 2011; 4(3): 266-272.
113. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100(5): 82.
114. Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Køber L, Treiman M, Holst JJ, Engstrøm T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33(12): 1491-9.
115. Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, Jørgensen E, Helqvist S, Saunamäki K, Terkelsen CJ, Schoos MM, Køber L, Clemmensen P, Treiman M, Engstrøm T. Exenatide reduces final infarct size in patients with ST-segmentelevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012; 5(2): 288-95.
116. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim KS. Cardioprotective effects of exenatide in patients with STsegment- elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 2013; 33(9): 2252-60.
117. Nathanson D, Zethelius B, Berne C, Lind L, Andrén B, Ingelsson E, Holst JJ, Nyström T. Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men. Diabet Med 2011; 28(3): 301-5.
118. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon- like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12(9): 694-9.
119. Nathanson D, Ullman B, Löfström U, Hedman A, Frick M, Sjöholm A, Nyström T. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 2012; 55(4): 926-35.
120. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. The EXAMINE investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1327-35.
121. White WB, Pratley R, Fleck P, Munsaka M, Hisada M, Wilson C, Menon V. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15(7): 668-73.
122. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317-26.
123. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; for the SAVOR-TIMI 53 Steering Committee and Investigators. Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR - TIMI 53 Randomized Trial. Circulation. 2014 Sep 4. pii: CIRCULATIONAHA.114.010389. [Epub ahead of print].
124. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin Use in Patients With Diabetes and Heart Failure: A Population-Based Retrospective Cohort Study. JACC Heart Fail 2014 Jun 25.
125. Iqbal N, Parker A, Frederich R, Donovan M, Hirshberg B. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol 2014; 13: 33.
126. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2014; 13: 33.
127. Mathieu C, Barnett AH, Brath H, Conget I, de Castro JJ, Göke R, Márquez Rodriguez E, Nilsson PM, Pagkalos E, Penfornis A, Schaper NC, Wangnoo SK, Kothny W, Bader G. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract 2013; 67(10): 947-56.
128. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20(4): 224-35.
129. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010; 12(6): 485-94.
130. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011; 27 Suppl 3: 57-64.
131. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, O'Keefe JH. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012; 110(6): 826-33.
132. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated metaanalysis of a phase 3 programme. Cardiovasc Diabetol 2012; 11: 3.
133. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther 2014; 32(4): 147-58.
134. Zhang Y, Hong J, Chi J, Gu W, Ning G, Wang W. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 2014; 30(3): 241-56.
135. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a metaanalysis. Diabetes Obes Metab 2014; 16(1): 30-7.